Related Experiment Videos

Rapid efficacy of anifrolumab in refractory cutaneous dermatomyositis

Chloé Grolleau1,2, Thibault Mahévas1, Pascale Daniel3

  • 1AP-HP, Hôpital Saint-Louis, Service de Dermatologie, Paris, France.

Journal of the European Academy of Dermatology and Venereology : JEADV
|July 14, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Anifrolumabconnective tissue diseasesdermatomyositisinterferonmyositisreal world

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...